NCT04400292Active, not recruiting
Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging
Does the Concept of the Sentinel Lymph Node Apply to Esophageal Cancer? A Prospective Assessment of Near-infrared Image-guided Lymphatic Mapping and Sentinel Lymph Node Identification in Esophageal Cancer
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 20 May 2020
- Start date
- 20 May 2020
- Primary completion date
- 31 May 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04400292
What you commit to
- Study type: Interventional
- Participants enrolled: 90
- From 20 May 2020 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No plan to undergo surgical resection.
- Prior diagnosis of severe hepatic or renal dysfunction.
Other illness
- Severe iodide or seafood allergy.
- Patients with Stage IVB or M1 disease (AJCC Cancer Staging Manual, 8th edition)
Other
- Women of childbearing potential without a negative pregnancy test; or women who are lactating.
- Patients with local recurrence and planning to undergo salvage esophagectomy
Who the study is looking for
- Pathological diagnosis of adenocarcinoma tumor located in distal 1/3 of esophagus or esophagogastric junction , with a plan to undergo minimally invasive esophagectomy.
- All patients with Stage IVA (AJCC Cancer Staging Manual, 8th edition) disease will be eligible
- ≥18 years of age.
- Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study and for standard surgical resection.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.